Dr. Reddy’s Laboratories Ltd ADR (RDY)

Exchange: USA Stocks • Country: India • Currency: USD • Type: Common Stock • ISIN: US2561352038

Generic Medicines, Active Pharmaceutical Ingredients, Biologics

Dr. Reddy's Laboratories Limited is a global pharmaceutical company that operates through three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others.

The Global Generics segment is responsible for manufacturing and marketing a wide range of prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages with therapeutic equivalence to branded formulations. This segment also delves into the biologics business, which involves developing and manufacturing complex medicines made from living organisms.

The PSAI segment focuses on manufacturing and marketing active pharmaceutical ingredients and intermediates, which are essential components for finished pharmaceutical products. This segment also provides contract research services, where they collaborate with clients to develop custom-made active pharmaceutical ingredients and steroids according to specific requirements.

The Others segment is dedicated to developing innovative therapies in areas such as oncology and inflammation. They also invest in research and development of differentiated formulations, which involves creating unique and improved versions of existing medicines. Additionally, this segment provides digital healthcare services and information technology-enabled business support services, which aim to improve healthcare outcomes and streamline business operations.

The company's product portfolio spans across various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. This diversified portfolio enables Dr. Reddy's Laboratories to cater to a broad range of healthcare needs.

Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited has established itself as a prominent player in the global pharmaceutical industry. For more information, visit their website at https://www.drreddys.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Dr. Reddy’s Laboratories Ltd ADR (RDY)

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Dr. Reddy’s Laboratories Ltd ADR (RDY)

RDY Stock Overview

Market Cap in USD 11,570m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2001-04-11

RDY Stock Ratings

Growth 5y 5.47
Fundamental 54.5
Dividend 7.82
Rel. Performance vs Sector 1.38
Analysts 3.00/5
Fair Price Momentum 67.31 USD
Fair Price DCF 3133.28 USD

RDY Dividends

Yield 12m 1.37%
Yield on Cost 5y 2.67%
Dividends CAGR 5y 11.45%
Payout Consistency 94.1%

RDY Growth Ratios

Growth 12m 32.16%
Growth Correlation 12m 52%
Growth Correlation 3m -59%
CAGR 5y 14.29%
CAGR/Mean DD 5y 1.14
Sharpe Ratio 12m 1.39
Alpha vs SP500 12m 16.37
Beta vs SP500 5y weekly 0.47
ValueRay RSI 38.39
Volatility GJR Garch 1y 22.83%
Price / SMA 50 -1.55%
Price / SMA 200 1.17%
Current Volume 249.1k
Average Volume 20d 268.6k

External Links for RDY Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of RDY stocks?
As of May 30, 2024, the stock is trading at USD 70.94 with a total of 249,148 shares traded.
Over the past week, the price has changed by +2.93%, over one month by -4.68%, over three months by -7.98% and over the past year by +32.16%.
What are the forecast for RDY stock price target?
According to ValueRays Forecast Model, RDY Dr. Reddy’s Laboratories Ltd ADR will be worth about 72.7 in May 2025. The stock is currently trading at 70.94. This means that the stock has a potential upside of +2.48%.
Issuer Forecast Upside
Wallstreet Target Price 80.9 14.0
Analysts Target Price 70.1 -1.17
ValueRay Target Price 72.7 2.48